HLS Therapeutics Inc.
TSX:HLS.TO
3.26 (CAD) • At close September 13, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | HLS Therapeutics Inc. |
Symbool | HLS.TO |
Munteenheid | CAD |
Prijs | 3.26 |
Beurswaarde | 103,645,180 |
Dividendpercentage | 0% |
52-weken bereik | 3 - 5.48 |
Industrie | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Mr. Craig Stuart Millian M.B.A. |
Website | https://www.hlstherapeutics.com |
An error occurred while fetching data.
Over HLS Therapeutics Inc.
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (CAD)
Cijfers zijn in miljoenen (CAD)